Lyell Immunopharma Inc.

04/07/2024 | Press release | Distributed by Public on 04/07/2024 17:42

AACR 2024: Preclinical ROR1-Targeted CAR T-Cell Product Incorporating Four Novel Reprogramming Technologies Designed for Effective Cell Therapy for Solid Tumors